Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: A comprehensive review from 2003 to 2023

Abstract

The increasing threat of antibiotic resistance has necessitated the development of new antibacterial agents. 33 novel antibacterial agents have been approved by the U.S. Food and Drug Administration (FDA) within the two-decade timeframe from 2003 to 2023. These novel antibacterial agents included new chemical classes, such as lipopeptides, 18-membered macrolides, diaromatic quinolones, and nitroimidazoles, as well as modified existing classes, such as quinolones, tetracyclines, β-lactams, macrolides, oxazolidinones, and aminoglycosides. Nonetheless, during these twenty years, approval for new antibiotics was notably absent in 6 different years, and the total number of antibiotics approved was considerably less than that of other drug classes, including anticancer drugs. In this review, we provide an extensive analysis of the synthetic approaches and therapeutic applications of these approved antibacterial agents. We believe that this review will help further research on potential antibacterial agents for clinical use and development of next generation of antibacterial agents.

Keywords: Antibacterial agents; FDA approved; Synthetic approach; Therapeutic applications.